Do you want to read an article? Please log in or register.
Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis
Type 1 Diabetes
COMMENTED
Related content
COMMENTED
Type 1 Diabetes
Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis
Eur J Endocrinol.
Nederstigt C, Uitbeijerse B, Janssen L, Corssmit EP, de Koning E, Dekkers O
doi: 10.1530/EJE-18-0515.
Type 1 Diabetes
Systematic Literature Review and Network Meta-Analysis of SGLT Inhibitors versus Metformin as Add-On to Insulin in Type 1 Diabetes
Diabetes Obes Metab.
Langford BE, Evans M, Haskins-Coulter T, O'Connor ME, Cant H, Eddowes LA, Edmonds C, Tank A
doi: 10.1111/dom.13863.
COMMENTED
Type 2 Diabetes
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Diabetes Obes Metab.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V
doi: 10.1111/dom.
COMMENTED
Type 2 Diabetes
Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Apostolos Tsapas, Bekiari E
doi: 10.1111/dom.14108.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
BMJ
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
doi: 10.1136/bmj.m4573
RECOMMENDED
Type 2 Diabetes
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Lancet Diabetes Endocrinol.
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ
doi: 10.1016/
COMMENTED
Diabetes - GeneralType 2 Diabetes
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Diabetes Care.
de Carvalho LSF, Campos AM, Sposito AC
doi: 10.2337/dc17-1464.
Type 1 DiabetesGlycemic ControlPediatric Diabetes
Effect of early glycaemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic Review and Meta-analysis
Pediatr Diabetes.
Mazarello Paes V, Barrett JK, Taylor-Robinson DC, Chesters H, Charalampopoulos D, Dunger DB, Viner RM6, Stephenson TJ
doi: 10.1111/pedi.12850.
Type 2 DiabetesDiabetic Complications
SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
Diabetes Obes Metab.
Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X
doi: 10.1111/dom.14075.